Cambridge Investment Research Advisors Inc. Has $464,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Cambridge Investment Research Advisors Inc. reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 3.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 46,027 shares of the company’s stock after selling 1,741 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Roivant Sciences were worth $464,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ROIV. Parallel Advisors LLC raised its stake in shares of Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company’s stock valued at $25,000 after purchasing an additional 1,108 shares in the last quarter. Treasurer of the State of North Carolina raised its stake in shares of Roivant Sciences by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company’s stock valued at $2,213,000 after purchasing an additional 1,170 shares in the last quarter. WINTON GROUP Ltd raised its stake in shares of Roivant Sciences by 1.5% in the fourth quarter. WINTON GROUP Ltd now owns 92,526 shares of the company’s stock valued at $1,095,000 after purchasing an additional 1,332 shares in the last quarter. Covestor Ltd raised its stake in shares of Roivant Sciences by 7.5% in the fourth quarter. Covestor Ltd now owns 20,634 shares of the company’s stock valued at $245,000 after purchasing an additional 1,444 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after purchasing an additional 1,507 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, June 18th. The Goldman Sachs Group assumed coverage on Roivant Sciences in a research report on Thursday. They issued a “buy” rating and a $19.00 price target on the stock.

Insider Activity at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 577,007 shares of the business’s stock in a transaction on Friday, June 20th. The stock was sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the completion of the transaction, the insider owned 37,284,108 shares of the company’s stock, valued at approximately $427,275,877.68. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction on Friday, June 20th. The stock was sold at an average price of $11.45, for a total value of $1,145,000.00. Following the sale, the chief operating officer owned 1,462,223 shares in the company, valued at $16,742,453.35. This represents a 6.40% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,464,462 shares of company stock valued at $39,098,856. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $11.57 on Friday. The firm has a market cap of $7.87 billion, a P/E ratio of -46.28 and a beta of 1.15. The stock’s 50-day moving average is $11.12 and its 200-day moving average is $10.87. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.15). The company had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative net margin of 225.71% and a negative return on equity of 14.76%. During the same quarter in the prior year, the business earned ($0.23) earnings per share. Equities analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.